Please login to the form below

Not currently logged in
Email:
Password:

Merck defeated in antibiotic patent case in US

Loses four patents protecting Cubicin from generic competition
Merck

Merck & Co is in danger of losing patent protection for an antibiotic that was a key factor in its $8.4bn acquisition of Cubist Pharma last year.

The US Court of Appeals for the Federal Circuit this week upheld a lower court ruling that invalidated four patents protecting Cubicin (daptomycin) from generic competition until 2020. One patent was upheld, but that expires in June 2016.

The company - known as MSD outside the US and Canada - said in a statement it is "considering its next steps, which may include seeking further review at the Federal Circuit or Supreme Court."

The basic patent on daptomycin, which was originally developed by Eli Lilly and acquired by Cubist in 1997, expired in the US in 2002, according to court papers.

Cubicin is an injectable antibiotic indicated for complicated skin and skin structure infections caused by Gram-positive bacteria, as well as bacteraemia caused by Staphylococcus aureus. It is the top-selling antibiotic in Merck's portfolio with sales of $805m in the first nine months of the year.

Last December, a Delaware federal judge invalidated the four Cubicin patents on the grounds of obviousness - on the same day that Merck announced its intention to buy Cubist - in a case brought by Pfizer subsidiary Hospira which plans to launch a generic version of the drug.

Merck pressed ahead with the Cubist acquisition regardless, closing the deal in the first quarter of the year.

In addition to Cubicin, buying Cubist has also given Merck Sivextro (tedizolid phosphate) - anther treatment for skin and skin structure infections, and Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal and urinary tract infections.

Neither of these drugs make significant revenues at the moment and sales are not broken out in Merck's financial accounting, although Zerbaxa in particular has been predicted to become a blockbuster in time.

Nevertheless, if Cubicin succumbs to generic competition early it will lend weight to the arguments of investors who have claimed Merck paid too much for Cubist.

Article by
Phil Taylor

13th November 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics